Myriad GC Soft-Pedals Importance Of High Court IP Ruling

Law360, Philadelphia (September 23, 2013, 3:13 PM EDT) -- The general counsel of Myriad Genetics Inc. on Monday downplayed the significance of the U.S. Supreme Court’s June ruling that human genes cannot be patented, arguing that research trends toward a focus on a collage of genes will diminish the ramifications of the decision.

Delivering as the keynote speech at the Licensing Executives Society’s annual conference, Richard Marsh emphasized that within the world of diagnostic research, this shift  will make patents on methods far more consequential than “composition of matter” patents.

As a result of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.